Advertisement

Lipids

, Volume 47, Issue 11, pp 1031–1041 | Cite as

Fish Oil Supplementation Reduces Cachexia and Tumor Growth While Improving Renal Function in Tumor-Bearing Rats

  • Isabela Coelho
  • Fernando Casare
  • Danielle C. T. Pequito
  • Gina Borghetti
  • Ricardo K. Yamazaki
  • Gleisson A. P. Brito
  • Marcelo Kryczyk
  • Luiz Claudio Fernandes
  • Terezila M. Coimbra
  • Ricardo FernandezEmail author
Original Article

Abstract

The objective of the present work was to study the renal function of healthy and tumor-bearing rats chronically supplemented with fish oil (FO), a source of n-3 polyunsaturated fatty acids. Weanling male rats were divided in two groups, one control (C) and another orally supplemented for 70 days with FO (1 g/kg body weight). After this time, half the animals of each group were injected in the right flank with a suspension of Walker 256 tumor cells (W and WFO). The W group had less proteinemia reflecting cachectic proteolysis, FO reversed this fact. Tumor weight gain was also reduced in WFO. Glomerular filtration rate (GFR) was not different in FO or W compared to C, but was higher in WFO. Renal plasma flow (RPF) was higher in the FO supplemented groups. The W group had lower plasma osmolality than the C group, but FO supplementation resulted in normalization of this parameter. Fractional sodium excretion (FENa+) of FO rats was similar to C. Proximal Na+ reabsorption, evaluated by lithium clearance, was similar among the groups. Urinary thromboxane B2 (TXB2) excretion was lower in the supplemented groups. The number of macrophages in renal tissue was higher in W compared to C rats, but was lower in WFO rats compared to W rats. In conclusion, FO supplementation resulted in less tumor growth and cachexia, and appeared to be renoprotective, as suggested by higher RPF and GFR.

Keywords

Fish oil supplementation Fatty acid Renal function Cachexia Glomerular filtration Sodium excretion 

Abbreviations

FO

Fish oil

PUFA

Polyunsaturated fatty acid(s)

EPA

Eicosapentaenoic acid

DHA

Docosahexaenoic acid

ARA

Arachidonic acid

PG

Prostaglandins

TX

Thromboxanes

AVP

Arginine-vasopressin hormone

C

Control rats

W

Walker 256 tumor-bearing rats

WFO

Walker 256 tumor-bearing rats supplemented with fish oil

PAH

p-Aminohippuric acid

RBF

Renal plasma flow

GFR

Glomerular filtration rate

FENa+

Fractional sodium excretion

CLi+

Lithium clearance

PFRNa+

Proximal fractional reabsorption of Na+

PPFRNa+

Post-proximal fractional excretion of Na+

DDNa+

Na+ distal delivery

MCP-1

Chemokine monocyte chemoattractant protein 1

TAG

Serum triacylglycerol

COX

Cyclooxygenase

Notes

Acknowledgments

Authors thank Dr. Carolina A. Freire for the osmolality readings and useful suggestions. Research supported by Fundação Araucária, Paraná, Brasil. Luiz C. Fernandes and Terezila M. Coimbra were supported by grants of the Conselho Nacional de Pesquisas (CNPq), Brasil.

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

11745_2012_3715_MOESM1_ESM.doc (34 kb)
Supplementary material 1 (DOC 34 kb)

References

  1. 1.
    Aguila MB, Pinheiro AR, Aquino JC, Gomes AP, Mandarim–De–Lacerda CA (2005) Different edible oil beneficial effects (canola oil, fish oil, palm oil, olive oil, and soybean oil) on spontaneously hypertensive rat glomerular enlargement and glomeruli number. Prostaglandins Other Lipid Mediat 76:74–85PubMedCrossRefGoogle Scholar
  2. 2.
    An WS, Kim HJ, Cho K, Vaziri ND (2009) Omega–3 fatty acid supplementation attenuates oxidative stress, inflammation, and tubulointerstitial fibrosis in the remnant kidney. Am J Physiol Renal Physiol 297:F895–F903PubMedCrossRefGoogle Scholar
  3. 3.
    Baggio B, Budakovic A, Priante G, Gambaro G, Manzato E, Khan S (2002) Dietary fatty acid supplementation modulates the urinary excretion of calcium and oxalate in the rat. Insight into calcium lithogenesis. Nephron 91:486–491PubMedCrossRefGoogle Scholar
  4. 4.
    Bayorh MA, Williams EF, Ogbolu EC, Walker CE, Manor EL, Brown LG, Chenault VM (1996) Effects of MaxEPA on salt-induced hypertension: relationship to [3H]nitrobenzylthioinosine binding sites. Clin Exp Hypertens 18:37–49PubMedCrossRefGoogle Scholar
  5. 5.
    Blackburn GL, Maini BS, Bistrian BR, Mcdermmott WV Jr (1977) The effect of cancer on nitrogen, electrolyte and mineral metabolism. Cancer Res 37:2348–2353PubMedGoogle Scholar
  6. 6.
    Boer WH, Fransen R, Shirley DG, Walter SJ, Boer P, Koomans HA (1995) Evaluation of lithium clearance method: direct analysis of tubular lithium handling by micropuncture. Kidney Int 47:1023–1030PubMedCrossRefGoogle Scholar
  7. 7.
    Brown SA, Brown CA, Crowell WA, Barsanti JA, Kang C, Allen T, Cowell C, Finco DR (2000) Effects of dietary polyunsaturated fatty acid supplementation in early renal insufficiency in dogs. J Lab Clin Med 135:275–286PubMedCrossRefGoogle Scholar
  8. 8.
    Calder PC (2006) Polyunsaturated fatty acids and inflammation. Prostaglandins Other Lipid Mediat 75:197–202Google Scholar
  9. 9.
    Câmara NO, Martins JO, Landgraf RG, Jancar S (2009) Emerging roles for eicosanoids in renal diseases. Curr Opin Nephrol Hypertens 18:21–27PubMedCrossRefGoogle Scholar
  10. 10.
    Caygill CPJ, Charlett A, Hill MJ (1996) Fat, fish, fish oil and cancer. Br J Cancer 74:159–164PubMedCrossRefGoogle Scholar
  11. 11.
    Coimbra TM, Janssen U, Gröne HJ, Ostendorf T, Kunter U, Schmidt H, Brabant G, Floege J (2000) Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int 57:167–182PubMedCrossRefGoogle Scholar
  12. 12.
    Culp BR, Titus BG, Lands WE (1979) Inhibition of prostaglandin biosynthesis by eicosapentaenoic acid. Prostaglandins Med 3:269–278PubMedCrossRefGoogle Scholar
  13. 13.
    De Caterina R, Endres S, Kristensen SD, Schmidt EB (1994) N–3 fatty acids and renal diseases. Am J Kidney Dis 24:397–415PubMedGoogle Scholar
  14. 14.
    Diaz Encarnacion MM, Warner GM, Cheng J, Gray CE, Nath KA, Grande JP (2011) N-3 Fatty acids block TNF-α-stimulated MCP-1 expression in rat mesangial cells. J Physiol Renal Physiol 300:1142–1151CrossRefGoogle Scholar
  15. 15.
    DiBona GF (1986) Prostaglandins and nonsteroidal anti-inflammatory drugs. Effects on renal hemodynamics. Am J Med 17:12–21CrossRefGoogle Scholar
  16. 16.
    Dolegowska B, Pikuła E, Safranow K, Olszewska M, Jakubowska K, Chlubek D, Gutowski P (2006) Metabolism of eicosanoids and their action on renal function during ischaemia and reperfusion: the effect of alprostadil. Prostaglandins Other Lipid Mediat 75:403–411Google Scholar
  17. 17.
    Donadio JV, Grande JP (2004) The role of fish oil/omega-3 fatty acids in the treatment of IgA nephropathy. Semin Nephrol 24:225–243PubMedCrossRefGoogle Scholar
  18. 18.
    Donadio JV (2001) N-3 Fatty acids and their role in nephrologic practice. Curr Opin Nephrol Hypertens 10:639–642PubMedCrossRefGoogle Scholar
  19. 19.
    Dusing R, Struck A, Göbel BO, Weisser B, Vetter H (1990) Effects of n-3 fatty acids on renal function and renal prostaglandin E metabolism. Kidney Int 38:315–319PubMedCrossRefGoogle Scholar
  20. 20.
    Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G, Marks D, Mitch WE, Muscaritoli M, Najand A, Ponikowski P, Rossi Fanelli F, Schambelan M, Schols A, Schuster M, Thomas D, Wolfe R, Anker SD (2008) Cachexia: a new definition. Clin Nutr 27:793–799PubMedCrossRefGoogle Scholar
  21. 21.
    Fassett RG, Gobe GC, Peake JM, Coombes JS (2010) Omega-3 polyunsaturated fatty acids in the treatment of kidney disease. Am J Kidney Dis 56:728–742PubMedCrossRefGoogle Scholar
  22. 22.
    Fearon KCH, Barber MD, Moses AG, Ahmedzai SH, Taylor GS, Tisdale MJ, Murray GD (2006) Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol 24:3401–3407PubMedCrossRefGoogle Scholar
  23. 23.
    Fernandes LC, Carpinelli AR, Hell NS, Curi R (1991) Improvement of cancer cachexia and decrease of Walker 256 tumor growth by insulin administration in rats. Cancer Ther Control 1:259–268Google Scholar
  24. 24.
    Fernandez R, Piechnik J, Fabris R, Malnic G, Fernandes LC (2004) Effect of chronic fish oil supplementation on renal function of normal and cachectic rats. Braz J Med Biol Res 37:1481–1489PubMedCrossRefGoogle Scholar
  25. 25.
    Francescato HDC, Marin ECS, Cunha FQ, Costa RS, Silva CGA, Coimbra TM (2011) Role of endogenous hydrogen sulfide on renal damage induced by adriamycin injection. Arch Toxicol 85:1597–1606PubMedCrossRefGoogle Scholar
  26. 26.
    Friedman A, Moe S (2006) Review of the effects of omega-3 supplementation in dialysis patients. Clin J Am Soc Nephrol 1:182–192PubMedCrossRefGoogle Scholar
  27. 27.
    Fuehr J, Kaczmarczyk J, Kruttgen CD (1955) A simple colorimetric method of inulin determination in renal clearance studies on metabolically normal subjects and diabetics. Klin Wochenschr 33:729–730CrossRefGoogle Scholar
  28. 28.
    Giacosa A, Frascio F, Sukkar SG, Roncella S (1996) Food intake and body composition in cancer cachexia. Nutrition 12:S20–S23PubMedGoogle Scholar
  29. 29.
    Grossberg AJ, Scarlett JM, Marks DL (2010) Hypothalamic mechanisms in cachexia. Physiol Behav 100:478–489PubMedCrossRefGoogle Scholar
  30. 30.
    Hao C, Breyer MD (2007) Physiologic and pathophysiologic roles of lipid mediators in the kidney. Kidney Int 71:1105–1115PubMedCrossRefGoogle Scholar
  31. 31.
    Hao C, Breyer MD (2008) Physiological regulation of prostaglandins in the kidney. Ann Rev Physiol 70:357–377CrossRefGoogle Scholar
  32. 32.
    Jiang WG, Bryce RP, Horrobin DF (1998) Essential fatty acids: molecular and cellular basis of their anti-cancer action and clinical implications. Crit Rev Oncol Hematol 27:179–209PubMedCrossRefGoogle Scholar
  33. 33.
    Kim G (2008) Renal effects of prostaglandins and cyclooxygenase-2 inhibitors. Electrolyte Blood Press 6:35–41CrossRefGoogle Scholar
  34. 34.
    Lauretani F, Semba RD, Bardinelli S, Miler ER, Ruggiero C, Cherubini A, Guralnik JM, Ferrucci L (2008) Plasma polyunsaturated fatty acids and the decline of renal function. Clin Chem 54:475–481PubMedCrossRefGoogle Scholar
  35. 35.
    Logan JL, Michael UF, Benson B (1992) Dietary fish oil interferes with renal arachidonic acid metabolism in rats: correlations with renal physiology. Metabolism 41:382–389PubMedCrossRefGoogle Scholar
  36. 36.
    Luft FC (2007) Cachexia has only one meaning. J Mol Med 85:783–785PubMedCrossRefGoogle Scholar
  37. 37.
    Morrison AR (1986) Biochemistry and pharmacology of renal arachidonic acid metabolism. Am J Med 80:3–11PubMedCrossRefGoogle Scholar
  38. 38.
    Mund RC, Pizato N, Bonatto S, Nunes EA, Vicenzi T, Tanhoffer R, de Oliveira HH, Curi R, Calder PC, Fernandes LC (2007) Decreased tumor growth in Walker 256 tumor-bearing rats chronically supplemented with fish oil involves COX-2 and PGE2 reduction associated with apoptosis and increased peroxidation. Prostaglandins Other Lipid Mediat 76:113–120Google Scholar
  39. 39.
    Munger K, Baylis C (1988) Sex differences in renal hemodynamics in rats. Am J Physiol 254:223–231Google Scholar
  40. 40.
    Pandalai PK, Pilat MJ, Yamazaki K (1996) The effects of omega-3 and omega-6 fatty acids on in vitro prostate cancer growth. Anticancer Res 16:815–820PubMedGoogle Scholar
  41. 41.
    Peake J, Gobe G, Fassett R, Coombes J (2011) The effects of dietary fish oil on inflammation, fibrosis and oxidative stress associated with obstructive renal injury in rats. Mol Nutr Food Res 55:400–410PubMedCrossRefGoogle Scholar
  42. 42.
    Pinto JA Jr, Folador A, Bonato SJ, Aikawa J, Yamazaki RK, Pizato N, Facin M, Grohs H, de Oliveira HH, Naliwaiko K, Ferraz AC, Nishiyama A, Fernandez R, Curi R, Fernandes LC (2004) Fish oil supplementation in F1 generation associated with naproxen, clenbuterol, and insulin administration reduce tumor growth and cachexia in Walker 256 tumor-bearing rats. J Nutr Biochem 15:358–365PubMedCrossRefGoogle Scholar
  43. 43.
    Raymond C, Harris Jr, Matthew D, Breyer BM (2008) Arachidonic Acid Metabolites and the Kidney. In: The Kidney, chap. 11Google Scholar
  44. 44.
    Remuzzi G, Bertani T (1998) Pathophysiology of progressive nephropathies. N Engl J Med 339:1448–1456PubMedCrossRefGoogle Scholar
  45. 45.
    Rettori O, Vieira-Matos AN, Gontijo JR (2000) Re-assessment of the renal hydrosaline dysfunction in rats bearing the Walker-256 tumor. Ren Fail 22:769–784PubMedCrossRefGoogle Scholar
  46. 46.
    Ruxton CHS, Reed SC, Simpson MJA, Millington KL (2004) The health benefits of omega-3 polyunsaturated fatty acids: a review of the evidence. J Hum Nutr Diet 17:449–459PubMedCrossRefGoogle Scholar
  47. 47.
    Schlondorff D (1995) The role of chemokines in the initiation and progression of renal disease. Kidney Int 47:S44–S47Google Scholar
  48. 48.
    Schmitz PG, O’donnell MP, Kasiske BL, Keane WF (1991) Glomerular hemodynamic effects of dietary polyunsaturated fatty acid supplementation. J Lab Clin Med 18:129–135Google Scholar
  49. 49.
    Shapiro H, Theilla M, Attal-Singer J, Singer P (2011) Effects of polyunsaturated fatty acid consumption in diabetic nephropathy. Nat Rev Nephrol 7:110–121PubMedCrossRefGoogle Scholar
  50. 50.
    Simopoulos AP (2008) The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp Biol Med 233:674–688CrossRefGoogle Scholar
  51. 51.
    Smith H, Finkelstein N, Aliminosa L, Crawford B, Graber M (1945) The renal clearances of substituted hippuric acid derivates and other aromatic acids in dog and man. J Clin Invest 24:388–404PubMedCrossRefGoogle Scholar
  52. 52.
    Svendsen KB, Bech JN, Sørensen TB, Pedersen EB (2000) A comparison of the effects of etodolac and ibuprofen on renal haemodynamics, tubular function, rennin, vasopressin and urinary excretion of albumin and α-glutathione-S-transferase in healthy subjects: a placebo-controlled cross-over study. Eur J Clin Pharmacol 56:383–388PubMedCrossRefGoogle Scholar
  53. 53.
    Thomsen K, Nielsen CB, Flyvbjerg A (2002) Effects of glycine on glomerular filtration rate and segmental tubular handling of sodium in conscious rats. Clin Exp Pharmacol Physiol 29:449–454PubMedCrossRefGoogle Scholar
  54. 54.
    Tisdale MJ (2009) Mechanisms of cancer cachexia. Physiol Rev 89:381–410PubMedCrossRefGoogle Scholar
  55. 55.
    Toal JN, Millar FK, Brooks RH, White J (1961) Sodium retention by rats bearing the Walker carcinosarcoma 256. Am J Physiol 200:175–181PubMedGoogle Scholar
  56. 56.
    Togni V, Ota CC, Folador A, Júnior OT, Aikawa J, Yamazaki RK, Freitas FA, Longo R, Martins EF, Calder PC, Curi R, Fernandes LC (2003) Cancer cachexia and tumor growth reduction in walker 256 tumor-bearing rats supplemented with n-3 polyunsaturated fatty acids for one generation. Nutr Cancer 46:52–58PubMedCrossRefGoogle Scholar
  57. 57.
    Usalan C, Emry S (1998) Membranoproliferative glomerulonephritis associated with small cell lung carcinoma. Int Urol Nephrol 30:209–213PubMedCrossRefGoogle Scholar
  58. 58.
    Zipser RD (1985) Effects of selective inhibition of thromboxane synthesis on renal function in humans. Am J Physiol 248:753–756Google Scholar
  59. 59.
    Zoja C, Abbate M, Remuzzi G (2006) Progression of chronic kidney disease: insights from animal models. Curr Opin Nephrol Hypertens 15:250–257PubMedCrossRefGoogle Scholar

Copyright information

© AOCS 2012

Authors and Affiliations

  • Isabela Coelho
    • 1
  • Fernando Casare
    • 1
  • Danielle C. T. Pequito
    • 1
  • Gina Borghetti
    • 1
  • Ricardo K. Yamazaki
    • 1
  • Gleisson A. P. Brito
    • 1
  • Marcelo Kryczyk
    • 1
  • Luiz Claudio Fernandes
    • 1
  • Terezila M. Coimbra
    • 2
  • Ricardo Fernandez
    • 1
    Email author
  1. 1.Departamento de Fisiologia, Setor de Ciências BiológicasUniversidade Federal do Paraná (UFPR) Centro Politécnico s/n.–Jd. das AméricasCuritibaBrazil
  2. 2.Departamento de Fisiologia–Faculdade de Medicina de Ribeirão PretoUniversidade de São Paulo (USP)Ribeirão PretoBrazil

Personalised recommendations